The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Fulvestrant administered in two different schedules: Pharmacokinetics, biological markers, and activity.
A. Felici
No relevant relationships to disclose
G. Naso
No relevant relationships to disclose
S. Di Segni
No relevant relationships to disclose
P. Vici
No relevant relationships to disclose
A. Antenucci
No relevant relationships to disclose
F. Angelini
No relevant relationships to disclose
L. Pizzuti
No relevant relationships to disclose
C. Mandoj
No relevant relationships to disclose
G. D'Auria
No relevant relationships to disclose
A. Fabi
No relevant relationships to disclose
A. Tata
No relevant relationships to disclose
F. Cognetti
No relevant relationships to disclose
P. Papaldo
No relevant relationships to disclose